Opko Health CEO Acquires $216,750 in Stock (OPK)
Opko Health (NYSE:OPK) CEO Phillip Md Et Al Frost bought 25,000 shares of Opko Health stock on the open market in a transaction dated Friday, August 1st. The stock was purchased at an average price of $8.67 per share, with a total value of $216,750.00. Following the completion of the purchase, the chief executive officer now directly owns 2,012,377 shares of the company’s stock, valued at approximately $17,447,309. The acquisition was disclosed in a filing with the SEC, which is available at this link.
Opko Health (NYSE:OPK) traded up 0.92% on Monday, hitting $8.82. 735,996 shares of the company’s stock traded hands. Opko Health has a 52 week low of $7.32 and a 52 week high of $12.95. The stock’s 50-day moving average is $8.90 and its 200-day moving average is $8.7. The company’s market cap is $3.649 billion.
Opko Health (NYSE:OPK) last released its earnings data on Friday, May 9th. The company reported ($0.11) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.10) by $0.01. The company had revenue of $22.30 million for the quarter, compared to the consensus estimate of $22.77 million. Analysts expect that Opko Health will post $-0.37 EPS for the current fiscal year.
OPK has been the subject of a number of recent research reports. Analysts at Jefferies Group reiterated a “buy” rating on shares of Opko Health in a research note on Wednesday, June 25th. They now have a $11.00 price target on the stock, down previously from $11.50. Separately, analysts at TheStreet upgraded shares of Opko Health from a “sell” rating to a “hold” rating in a research note on Friday, May 30th. Finally, analysts at TheStreet downgraded shares of Opko Health from a “hold” rating to a “sell” rating in a research note on Tuesday, May 13th. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $12.13.
OPKO Health, Inc (NYSE:OPK) is a multi-national biopharmaceutical and diagnostics company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.